Cumulative clinical benefit of treatment initiation with deucravacitinib vs. apremilast over 52 weeks for patients with moderate to severe plaque psoriasis in the POETYK PSO-1 trial
AUSTRALASIAN JOURNAL OF DERMATOLOGY(2023)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要